Sight Sciences (NASDAQ:SGHT – Get Free Report) and Microbot Medical (NASDAQ:MBOT – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, earnings, risk and dividends.
Profitability
This table compares Sight Sciences and Microbot Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sight Sciences | -63.30% | -47.28% | -32.72% |
| Microbot Medical | N/A | -218.30% | -158.17% |
Institutional and Insider Ownership
55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 16.3% of Microbot Medical shares are owned by institutional investors. 28.9% of Sight Sciences shares are owned by company insiders. Comparatively, 10.5% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
Analyst Recommendations
This is a summary of current ratings and target prices for Sight Sciences and Microbot Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sight Sciences | 0 | 5 | 2 | 0 | 2.29 |
| Microbot Medical | 0 | 0 | 1 | 0 | 3.00 |
Sight Sciences presently has a consensus target price of $4.68, suggesting a potential upside of 69.69%. Microbot Medical has a consensus target price of $9.00, suggesting a potential upside of 427.86%. Given Microbot Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Microbot Medical is more favorable than Sight Sciences.
Earnings and Valuation
This table compares Sight Sciences and Microbot Medical”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sight Sciences | $81.06 million | 1.73 | -$55.55 million | ($1.02) | -2.71 |
| Microbot Medical | N/A | N/A | -$10.74 million | ($0.80) | -2.13 |
Microbot Medical has lower revenue, but higher earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Sight Sciences beats Microbot Medical on 7 of the 13 factors compared between the two stocks.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
About Microbot Medical
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
